Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalised and versatile weight problems remedy via GIP receptor antagonism, in the present day declares that it’s going to ship an oral presentation on the 2026 Scientific Periods of the American Diabetes Affiliation® in New Orleans, Louisiana, going down from 5-8 June 2026. The presentation will function knowledge from the Firm’s first-in-human research of AT7687, its first-in-class Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist peptide, in each wholesome topics and folks dwelling with weight problems.
Along with the oral presentation, the Firm will current a poster highlighting preclinical knowledge from its research assessing the therapeutic potential of mixing AT7687 with cagrilintide, a twin amylin and calcitonin receptor (CTR) agonist with established weight-lowering efficacy.
Oral presentation particulars:
Title: First-in-human research demonstrates GIP-Receptor (GIPR) antagonist, AT7687, as well-tolerated and appropriate for once-weekly subcutaneous injection for remedy in folks dwelling with obesityDate: Sunday 7 June | 8:45 AM CTPresenter: Richard Nkulikiyinka
Poster presentation particulars:
More Read
Title: AT7687, a novel GIPR antagonist, mixed with cagrilintide, results in strong weight reduction and substantial enhancements in insulin sensitivity and physique composition in overweight insulin-resistant non-human primates Date: Sunday 7 June | 12:30 – 1:30 PM CTPresenter: Mads Tang-Christensen
-ENDS-
About Antag Therapeutics
More Read
Antag Therapeutics is a biotechnology firm redefining weight problems remedy with GIPR antagonism. Antag’s imaginative and prescient is that every one folks dwelling with weight problems, diabetes and chubby have a private remedy possibility, that goes past weight reduction to ship long-term sustained well being, with out having to compromise on tolerability.
Primarily based on a long time of analysis by GLP-1 pioneer Professor Jens Juul Holst, Antag’s lead molecule AT7687, is particularly designed to focus on and deactivate the GIP receptor, a genetically-validated pathway that contributes to fats storage, insulin resistance, and metabolic dysfunction. In pre-clinical research, AT7687 displays a superb tolerability profile, without having for titration, and enhancements throughout a variety of biomarkers associated to higher cardiovascular outcomes, more healthy physique composition.
Furthermore, AT7687 is a peptide particularly engineered and chosen for its simple and versatile formulation properties, uniquely positioning Antag to develop AT7687 as monotherapy or as co-formulation with different weight problems therapies.
This mechanistically distinct method suggests a paradigm shift within the remedy of weight problems, enabling a brand new type of remedy – designed to assist extra private, adaptable care – delivering more healthy, long-term outcomes for all folks with chubby or weight problems. The AT7687 Section 1 medical trial has been efficiently accomplished, and Section 2a research are anticipated to start out in mid-2026.
Antag Therapeutics has raised €80 million in a Collection A financing led by Versant Ventures with participation from Novo Holdings, SR One, Daybreak Biopharma, Pictet, Longview Ventures, and the Export and Funding Fund of Denmark (EIFO).
Study extra at www.antagtx.com.
More Read
Contacts
Antag Therapeutics
Philip Simply Larsen
Chief Government Officer, Antag Therapeutics
Antag Therapeutics Media Contacts
ICR Healthcare
Amber Fennell, Angela Grey, Evi Useh
